Molnlycke Health Care AB   Report issue

For profit Phase 4
Founded: Gothenburg Sweden (1849)
Status: No NME R&D (1849)

Organization Overview

First Clinical Trial
2011
NCT01439074
First Marketed Drug
1976
chlorhexidine (hibitane)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Caroline Scott | Molnlycke Health Care AB | MOLNLYCKE HLTH

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Burns (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 4